ClinicalTrials.gg
TerminatedNCT01450696HELOISEUpdated Nov 28, 2016Results posted

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

A Phase 3 interventional study of Capecitabine and Cisplatin in Gastric Cancer, sponsored by Hoffmann-La Roche. Terminated at 117 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
futility following planned interim analysis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.

Enrollment
14th of 97
296 · median 50
Started
2011
with 6 others
Phase 3
17 of 100
4 open now
Registered
59th of 100
by date
Lead sponsor
5 of 100
Hoffmann-La Roche

Among the 100 studies testing capecitabine in Stomach Neoplasms, this one is the 14th largest by enrollment of the 97 interventional ones that give a count, is one of 7 that started in 2011, is one of 17 in phase 3, and was the 59th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing capecitabine in Stomach Neoplasms, or all of them as a file.
02

Study summary

This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma. Participants who have not received prior treatment for metastatic disease will be randomized to receive Herceptin intravenously as either an 8-milligram per kilogram (mg/kg) loading dose followed by 6 mg/kg every 3 weeks (q3w) as standard of care or an 8-mg/kg loading dose followed by 10 mg/kg q3w until disease progression. Capecitabine will be administered for 6 cycles at a dose of 800 milligrams per meter-squared (mg/m\^2) orally twice a day on Days 1 to 14 of each 3-week cycle, and cisplatin will be administered intravenously for 6 cycles at a dose of 80 mg/m\^2 on Day 1 of each 3-week cycle. Herceptin will be continued until disease progression occurs.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the stomach or gastro-esophageal junction with disease documented to involve at least liver or lung or both
  • according to Version 1.1 or non-measurable evaluable disease
  • At least 2 organs involved in metastatic gastric tumor (including at least lung or liver or both) in addition to the site of primary tumor, where metastasis in distant lymph nodes, peritoneal metastasis, and malignant pleural effusion may count as "organs" in this context
  • -positive primary or metastatic tumor as assessed by central laboratory
  • Adequate renal function ( greater than equal to (≥) 45 milliliters per minute [mL/min])
  • (ECOG) performance status of 2

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy for locally advanced or disease
  • Prior gastrectomy (partial or total) for the underlying malignant disease under investigation
  • Prior therapy with an anti- agent and/or platinum-based chemotherapeutic agent
  • Residual relevant toxicity resulting from previous therapy
  • Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (such as jejunostomy probe and gastric or jejunostomy tubes) which may impair the ability to administer or absorb capecitabine
  • Current (significant or uncontrolled) gastrointestinal bleeding
  • Other within the last 5 years, except for carcinoma in situ of the cervix and basal or squamous cell carcinoma of the skin
  • History of documented congestive heart failure, angina pectoris requiring medication, (ECG) evidence of transmural myocardial infraction, poorly controlled hypertension, valvular heart disease, or high-risk uncontrollable arrhythmias
  • Baseline (LVEF) less than (\<) 50%, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
  • Chronic or high-dose therapy
  • History or clinical evidence of
  • Pregnant women
  • Active infection with (HIV), , or , or HIV-seropositive
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
296 participants (actual)

Study arms

  • Active comparator
    Capecitabine + Cisplatin + Herceptin (6 mg/kg)

    Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).

    Drug: Capecitabine · Drug: Cisplatin · Drug: Herceptin

  • Experimental
    Capecitabine + Cisplatin + Herceptin (10 mg/kg)

    Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).

    Drug: Capecitabine · Drug: Cisplatin · Drug: Herceptin

Interventions

  • Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).

  • Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).

  • Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

    Also known as: Trastuzumab

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Died - FAS

    The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the FAS with available data.

    Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)

  2. Overall Survival - FAS

    Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the FAS using the Kaplan-Meier approach. The 95 percent (%) confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

    Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)

Secondary outcomes

  1. Percentage of Participants Who Died - Per Protocol Set (PPS)

    The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.

    Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)

  2. Overall Survival - PPS

    Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the PPS using the Kaplan-Meier approach. The 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)

  3. Percentage of Participants With Disease Progression or Death - PPS

    Disease progression was defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 millimeters (mm). The percentage of participants who died or experienced disease progression as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.

    Time frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)

  4. Progression-Free Survival - PPS

    Progression-free survival was defined as the time between the day of randomization and the date of first documentation of disease progression or date of death, whichever occurred first, measured following RECIST Version 1.1 criteria. Disease progression was defined as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 mm. The 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)

  5. Percentage of Participants With Objective Response - PPS

    Objective response was defined as the occurrence of either a complete response (CR) or partial response (PR) as determined by RECIST Version 1.1 based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have reduction in short axis to \<10 mm. PR was defined as a ≥30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. The 95% CI was constructed using Blyth-Still-Casella method.

    Time frame: From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)

  6. Trastuzumab Cmin on Day 21 of Cycles 1 to 11 - FAS

    Cmin samples were obtained in all participants randomized to receive Herceptin (FAS). The observed Cmin was recorded, averaged among all participants, and expressed in μg/mL.

    Time frame: Day 21 of Cycle 1, 2, 3, 4, 5, 7, 9, 11 (cycle length = 21 days)

  7. Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS

    Trastuzumab serum concentration samples were obtained in all participants randomized to receive Herceptin (FAS). The observed concentration values were recorded, averaged among all participants, and expressed in μg/mL.

    Time frame: Pre-dose (0 minutes) and within 15 minutes after end of 2-hour Herceptin infusion on Day 1 of Cycle 1 (cycle length = 21 days)

07

Results

Posted Nov 28, 2016
Limitations and caveats
Trial was stopped for futility based on pre-planned interim analysis results.

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Started148148
Treated (safety population)147147
Completed00
Not completed148148
Withdrew: Never treated11
Withdrew: Death7784
Withdrew: Lost to follow-up33
Withdrew: Non-compliance10
Withdrew: Withdrawal by subject132
Withdrew: Study terminated by sponsor5358

Outcome measures

PrimaryPercentage of Participants Who Died - FAS

The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the FAS with available data.

Time frame:
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died - FAS
percentage of participantsCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Percentage of Participants Who Died - FAS46.854.0
PrimaryOverall Survival - FAS

Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the FAS using the Kaplan-Meier approach. The 95 percent (%) confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

Time frame:
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Reported as:
Median · months
Overall Survival - FAS
monthsCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Overall Survival - FAS12.485 (10.086 to 13.864)10.612 (9.363 to 12.419)
Statistical analysis
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Log Rank · p = 0.2401 · Hazard ratio (hr): 1.24 · 95% CI 0.86 to 1.78
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Log Rank · p = 0.1285 · Hazard ratio (hr): 1.32 · 95% CI 0.92 to 1.88
SecondaryPercentage of Participants Who Died - Per Protocol Set (PPS)

The percentage of participants who died as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.

Time frame:
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died - Per Protocol Set (PPS)
percentage of participantsCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Percentage of Participants Who Died - Per Protocol Set (PPS)51.559.4
SecondaryOverall Survival - PPS

Overall survival was defined as the time from the date of randomization to the date of death from any cause. Overall survival was estimated among participants from the PPS using the Kaplan-Meier approach. The 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
From date of randomization until death or premature withdrawal (up to approximately 31 months or data cutoff date of 13 February 2015)
Reported as:
Median · months
Overall Survival - PPS
monthsCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Overall Survival - PPS10.809 (8.082 to 14.752)9.363 (5.552 to 14.357)
Statistical analysis
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Log Rank · p = 0.9931 · Hazard ratio (hr): 1.00 · 95% CI 0.49 to 2.04
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Log Rank · p = 0.9458 · Hazard ratio (hr): 1.02 · 95% CI 0.52 to 2.02
SecondaryPercentage of Participants With Disease Progression or Death - PPS

Disease progression was defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 millimeters (mm). The percentage of participants who died or experienced disease progression as of the analysis data cutoff date of 13 February 2015 was reported among participants from the PPS.

Time frame:
From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death - PPS
percentage of participantsCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Percentage of Participants With Disease Progression or Death - PPS75.881.3
SecondaryProgression-Free Survival - PPS

Progression-free survival was defined as the time between the day of randomization and the date of first documentation of disease progression or date of death, whichever occurred first, measured following RECIST Version 1.1 criteria. Disease progression was defined as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline (nadir). In addition to the relative increase of 20%, the sum was also required to demonstrate an absolute increase of ≥5 mm. The 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Reported as:
Median · months
Progression-Free Survival - PPS
monthsCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Progression-Free Survival - PPS5.388 (2.793 to 7.721)4.370 (2.727 to 6.834)
Statistical analysis
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Log Rank · p = 0.6759 · Hazard ratio (hr): 1.13 · 95% CI 0.63 to 2.02
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Log Rank · p = 0.5764 · Hazard ratio (hr): 1.17 · 95% CI 0.67 to 2.05
SecondaryPercentage of Participants With Objective Response - PPS

Objective response was defined as the occurrence of either a complete response (CR) or partial response (PR) as determined by RECIST Version 1.1 based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have reduction in short axis to \<10 mm. PR was defined as a ≥30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. The 95% CI was constructed using Blyth-Still-Casella method.

Time frame:
From date of randomization until first occurrence of disease progression or death; assessed every 6 weeks (up to approximately 31 months or data cutoff date of 13 February 2015)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response - PPS
percentage of participantsCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Percentage of Participants With Objective Response - PPS57.6 (40.12 to 73.16)50.0 (31.89 to 68.11)
Statistical analysis
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Chi-squared · p = 0.5402 · Difference in response rates: -7.58 · 95% CI -31.75 to 16.60
  • Capecitabine + Cisplatin + Herceptin (6 mg/kg) vs Capecitabine + Cisplatin + Herceptin (10 mg/kg) · Odds ratio (or): 0.74 · 95% CI 0.28 to 1.96
SecondaryTrastuzumab Cmin on Day 21 of Cycles 1 to 11 - FAS

Cmin samples were obtained in all participants randomized to receive Herceptin (FAS). The observed Cmin was recorded, averaged among all participants, and expressed in μg/mL.

Time frame:
Day 21 of Cycle 1, 2, 3, 4, 5, 7, 9, 11 (cycle length = 21 days)
Reported as:
Mean · μg/mL
Trastuzumab Cmin on Day 21 of Cycles 1 to 11 - FAS
μg/mLCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Cycle 1 (n=100,99)17.1 ± 14.318.1 ± 18.1
Cycle 2 (n=93,76)19.2 ± 8.835.3 ± 19.4
Cycle 3 (n=77,71)23.2 ± 11.840.7 ± 20.6
Cycle 4 (n=73,61)25.9 ± 12.147.6 ± 20.2
Cycle 5 (n=70,60)26.7 ± 10.649.3 ± 23.2
Cycle 7 (n=51,44)31.4 ± 14.258.1 ± 27.6
Cycle 9 (n=31,24)33.7 ± 17.661.0 ± 23.9
Cycle 11 (n=24,16)32.5 ± 14.768.4 ± 35.9
SecondaryTrastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS

Trastuzumab serum concentration samples were obtained in all participants randomized to receive Herceptin (FAS). The observed concentration values were recorded, averaged among all participants, and expressed in μg/mL.

Time frame:
Pre-dose (0 minutes) and within 15 minutes after end of 2-hour Herceptin infusion on Day 1 of Cycle 1 (cycle length = 21 days)
Reported as:
Mean · μg/mL
Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS
μg/mLCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
Pre-dose (n=109,110)0.168 ± 1.690.0204 ± 0.123
End of infusion (n=110,111)126 ± 59.6137 ± 55.7

Adverse events

Collected over From date of randomization until 6 months after last dose of study drug or end of study (up to approximately 32 months or final data collection date of 25 August 2015). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine + Cisplatin + Herceptin (6 mg/kg)—35/147 (23.8%)123/147 (83.7%)
Capecitabine + Cisplatin + Herceptin (10 mg/kg)—38/147 (25.9%)122/147 (83%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
AnemiaBlood and lymphatic system disorders7/1476/147
VomitingGastrointestinal disorders5/1473/147
DiarrhoeaGastrointestinal disorders0/1474/147
Acute kidney injuryRenal and urinary disorders4/1472/147
Febrile neutropeniaBlood and lymphatic system disorders3/1473/147
Renal failureRenal and urinary disorders3/1470/147
Gastric haemorrhageGastrointestinal disorders2/1470/147
NauseaGastrointestinal disorders2/1470/147
Obstruction gastricGastrointestinal disorders2/1471/147
PneumoniaInfections and infestations2/1472/147
Most frequent other events
Showing 10 of 25
Most frequent other events
EventCapecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)
NeutropeniaBlood and lymphatic system disorders61/14769/147
NauseaGastrointestinal disorders55/14755/147
AnaemiaBlood and lymphatic system disorders47/14740/147
VomitingGastrointestinal disorders36/14742/147
Decreased appetiteMetabolism and nutrition disorders32/14727/147
DiarrhoeaGastrointestinal disorders24/14730/147
LeukopeniaBlood and lymphatic system disorders26/14724/147
ConstipationGastrointestinal disorders19/14725/147
FatigueGeneral disorders25/14723/147
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders14/14720/147

Baseline characteristics

The Full Analysis Set (FAS) population included all participants who were randomized in this study.

Age, Continuous
Age, Continuous(years)Capecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)Total
Mean59.5 ± 10.662.4 ± 10.760.0 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine + Cisplatin + Herceptin (6 mg/kg)Capecitabine + Cisplatin + Herceptin (10 mg/kg)Total
Female323769
Male116111227
08

Study locations

117 sites
  • La Jolla, California 92093, United States
  • Los Angeles, California 90033, United States
  • Whittier, California 90603, United States
  • Whittier, California 90606, United States
  • Goshen, Indiana 46526, United States
  • Wichita, Kansas 67214-3728, United States
  • New York, New York 10065, United States
  • Portland, Oregon 97239, United States
  • Charleston, South Carolina 29425, United States
  • Port Macquarie, New South Wales 2444, Australia
  • Wahroonga, New South Wales 2076, Australia
  • Woodville South, South Australia 5011, Australia
  • Murdoch, Western Australia 6150, Australia
  • Banja Luka, 78000, Bosnia and Herzegovina
  • Sarajewo, 71000, Bosnia and Herzegovina
  • Rio de Janeiro, RJ 20560-120, Brazil
  • Porto Alegre, RS 90610-000, Brazil
  • Barretos, SP 14784-400, Brazil
  • Sao Paulo, SP 01246-000, Brazil
  • Sorocaba, SP 18030-245, Brazil
  • Santiago, 7500921, Chile
  • Santiago, 8380456, Chile
  • Viña del Mar, 2520612, Chile
  • Beijing, 100050, China
  • Beijing, 100071, China
  • Beijing, 100142, China
  • Beijing, 100853, China
  • Changchun, 130012, China
  • Changsha, 410006, China
  • Changzhou, 213003, China
  • Guangzhou, 510060, China
  • Hangzhou, 310016, China
  • Nanjing, China
  • Shanghai, 200032, China
  • Wuhan, 430030, China
  • Zhengzhou, 450008, China
  • Brno, 656 53, Czech Republic
  • Olomouc, 775 20, Czech Republic
  • Praha 2, 128 08, Czech Republic
  • Praha 8, 180 81, Czech Republic
  • Berlin, 10117, Germany
  • Frankfurt, 60488, Germany
  • Mannheim, 68167, Germany
  • Budapest, 1097, Hungary
  • Budapest, 1145, Hungary
  • Pecs, 7623, Hungary
  • Szolnok, 5004, Hungary
  • Szombathely, 9700, Hungary
  • Veszprem, 8200, Hungary
  • Catanzaro, Calabria 88100, Italy
  • Napoli, Campania 80131, Italy
  • Bologna, Emilia-Romagna 40138, Italy
  • Reggio Emilia, Emilia-Romagna 42100, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Milano, Lombardia 20133, Italy
  • Ancona, Marche 60121, Italy
  • Florence, Toscana 50124, Italy
  • Pisa, Toscana 56100, Italy
  • Bundang City, 463-802, Korea, Republic of
  • Incheon, 405-760, Korea, Republic of
  • Seoul, 03722, Korea, Republic of
  • Seoul, 06351, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 130-872, Korea, Republic of
  • Seoul, 135-720, Korea, Republic of
  • Distrito Federal, 14080, Mexico
  • Mexico City, 06760, Mexico
  • Monterrey, 64020, Mexico
  • Oaxaca, 68000, Mexico
  • Auckland, 1023, New Zealand
  • Panama, 0834-02723, Panama
  • Arequipa, 04001, Peru
  • Arequipa, 5154, Peru
  • Lima, 1, Peru
  • Lima, 34, Peru
  • Lima, Lima 1, Peru
  • Lima, Lima 41, Peru
  • Trujillo, 13011, Peru
  • Manila, 1000, Philippines
  • Pasig City, 1605, Philippines
  • Krakow, 31-501, Poland
  • Lublin, 20-090, Poland
  • Warsaw, 00-973, Poland
  • Wieliszew, 05-135, Poland
  • Porto, 4200-072, Portugal
  • Ivanovo, 153040, Russian Federation
  • Omsk, 644013, Russian Federation
  • Ryazan, 390011, Russian Federation
  • St Petersburg, Russian Federation
  • Stavropol, 355045, Russian Federation
  • Tula, 300053, Russian Federation
  • Belgrade, 11000, Serbia
  • Nis, 18000, Serbia
  • Sremska Kamenica, 21204, Serbia
  • Bloemfontein, 9300, South Africa
  • Cape Town, 7506, South Africa
  • Johannesburg, 2193, South Africa
  • Barcelona, 08035, Spain
  • Barcelona, 08041, Spain
  • Madrid, 28046, Spain

Showing the first 100 of 117 sites across 25 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2011
First posted
Oct 12, 2011
Start
Dec 2011
Primary completionActual
Feb 2015
CompletionActual
Aug 2015
Results first posted
Nov 28, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01450696
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 12, 2011
Start date
Dec 2011
Primary completion
Feb 2015
Completion
Aug 2015
Results posted
Nov 28, 2016
Last update
Nov 28, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Cisplatin · Trastuzumab

Start the discussion